A multicenter, randomized, double-blind, placebo controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

被引：0
|
作者：
Zhang, Li
Zhou, Ting
Ma, Yuxiang
Yang, Yunpeng
Fang, Wenfeng
Zhao, Yuangyuan
Hong, Shaodong
Fang, Chan
Zhang, Jiexia
Zhang, Hongyu
Zhao, Hongyun
Huang, Yan
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[2] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[3] Hosp Tradit Chinese Med Zhongshan, Zhongshan, Peoples R China
[4] China State Key Lab Resp Dis, Guangzhou, Peoples R China
[5] Guangzhou Inst Resp Dis, Guangzhou, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China
[8] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China
[9] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS10142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10142
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR)
    Seckl, Michael J.
    Ottensmeier, Christian H.
    Cullen, Michael
    Schmid, Peter
    Ngai, Yenting
    Muthukumar, Dakshinamoorthy
    Thompson, Joyce
    Harden, Susan
    Middleton, Gary
    Fife, Kate M.
    Crosse, Barbara
    Taylor, Paul
    Nash, Stephen
    Hackshaw, Allan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1506 - +
  • [32] Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    VanAudenrode, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (10) : 761 - 762
  • [33] Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
    Lee, S.
    Rudd, R. M.
    Woll, P. J.
    Ottensmeier, C. H.
    James, L. E.
    Gower, N. H.
    Spiro, S. G.
    Jitlal, M.
    Hackshaw, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] DAILY ORAL PERIFOSINE IN COMBINATION WITH RADIOTHERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER: FIRST RESULTS OF A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER PHASE II STUDY
    Verheij, M.
    Karchmit, Y.
    Bakardjiev, S.
    Beliaukouski, V.
    Savu, M.
    Smickoska, S.
    Sindermann, H.
    Markivskyy, A.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S167 - S167
  • [35] Phase II/III clinical trial of randomized, double-blind, placebo-controlled combined with recombinant human endostatin in treatment of advanced non-small cell lung cancer
    Xu Liyan
    Shi He Heling
    Liu Zhe
    Zhu Yunzhong
    Li Baolan
    Zhang Shucai
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S354 - S354
  • [36] Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer
    Sun, Yan
    Wang, Jin Wan
    Liu, Yong Yu
    Yu, Qi Tao
    Zhang, Yi Ping
    Li, Kai
    Xu, Li Yan
    Luo, Su Xia
    Qin, Feng Zhan
    Chen, Zheng Tang
    Liu, Wen Chao
    Zhou, Qing Hua
    Chen, Qiang
    Nan, Ke Jun
    Liu, Xiao Qing
    Liu, Wei
    Liang, Hou Jie
    Lu, Hui Shan
    Wang, Xiu Wen
    Wang, Jie Jun
    Song, Shu Ping
    Tu, Yuan Rong
    Zhou, Jing Min
    Li, Wei Lian
    Yao, Chen
    THORACIC CANCER, 2013, 4 (04) : 440 - 448
  • [37] CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
    Goss, G.
    Darling, G. E.
    Westeel, V.
    Nakagawa, K.
    Massuti Sureda, B.
    Perrone, F.
    McLachlan, S-A.
    Kang, J. H.
    Wu, Y-L.
    Dingemans, A-M. C.
    Dziadziuszko, R.
    Okada, M.
    Greillier, L.
    Audigier-Valette, C.
    Sugawara, S.
    Nadal, E.
    Catino, A.
    Stockler, M. R.
    Ding, K.
    O'Callaghan, C.
    ANNALS OF ONCOLOGY, 2024, 35 : 1238 - 1238
  • [38] Randomized, double-blind, placebo-controlled, phase III multicentre study of paclitaxel plus carboplatin (TC) versus TC plus endostar in patients with advanced non-small cell lung cancer (NSCLC)
    Han Baohui
    Xiu Qingyu
    Wang Huiming
    Luo Yi
    Bai Chunxue
    Guo Shuliang
    Liu Wenchao
    Zhuang Zhixiang
    Zhang Yang
    Zhou Jianying
    Jing Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S354
  • [39] Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study
    Pectasides, D
    Mylonakis, N
    Farmakis, D
    Nikolaou, M
    Koumpou, M
    Katselis, I
    Gaglia, A
    Kostopoulou, V
    Karabelis, A
    Kosmas, C
    ANTICANCER RESEARCH, 2003, 23 (5B) : 4205 - 4211
  • [40] Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
    Kuang, Peng
    Chen, Zuhua
    Wang, JiaYuan
    Liu, Zhentao
    Wang, Jingyuan
    Gao, Jing
    Shen, Lin
    TRANSLATIONAL ONCOLOGY, 2017, 10 (03): : 367 - 377
12345